Intensity Therapeutics grants 5,500-share option to director

Intensity Therapeutics director Donovan Daniel received a stock option grant for 5,500 shares of common stock on July 16, 2026.

Rhea-AI Filing Summary

Intensity Therapeutics director Donovan Daniel received a stock option grant for 5,500 shares of common stock on July 16, 2026. The option has an exercise price of $4.90 per share, expires on July 16, 2036, and vests in four equal annual installments starting July 16, 2026, subject to continued service.

Insider Trade Summary

Grant/Award: 5,500 shares

Grant/Award 1 txn

Insider Donovan Daniel

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy Common Stock) F1	5,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy Common Stock) — 5,500 contracts (Direct)

Footnotes (1)

1. F1. This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2026.

Key Figures

Stock options granted: 5,500 shares Exercise price: $4.90 per share Expiration date: July 16, 2036 +1 more

4 metrics

Stock options granted 5,500 shares Stock Option grant to director on July 16, 2026

Exercise price $4.90 per share Exercise price of stock option granted July 16, 2026

Expiration date July 16, 2036 Expiration of stock option granted to director

Vesting schedule 4 equal annual installments Option vests annually beginning July 16, 2026, subject to continued service

Key Terms

Stock Option (right to buy Common Stock), exercise price, vesting

3 terms

Stock Option (right to buy Common Stock) financial

"security title "Stock Option (right to buy Common Stock)""

exercise price financial

"conversion or exercise price of 4.9000 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"This option will vest in four, equal, annual installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Intensity Therapeutics (INTS) report for Donovan Daniel?

Intensity Therapeutics reported that director Donovan Daniel received a stock option grant for 5,500 shares on July 16, 2026. The option is a right to buy common stock at a fixed exercise price, providing equity-based compensation linked to future company performance.

What are the key terms of the 5,500-share stock option granted by INTS?

The grant covers 5,500 shares of common stock with an exercise price of $4.90 per share and expires on July 16, 2036

How does the vesting schedule work for the Intensity Therapeutics (INTS) option grant?

The option will vest in four equal annual installments, beginning on July 16, 2026, subject to Donovan Daniel’s continued service with Intensity Therapeutics. Each year, one-quarter of the 5,500-option grant becomes exercisable until fully vested after four years.

When does the newly granted INTS stock option to Donovan Daniel expire?

The stock option granted to director Donovan Daniel has an expiration date of July 16, 2036. After that date, any unexercised portion of the 5,500 underlying shares can no longer be purchased at the $4.90 exercise price specified in the grant terms.

What is the difference between the transaction price and exercise price in the INTS Form 4?

The reported transaction price per option share is $0.00, reflecting a grant rather than a purchase, while the exercise price is $4.90 per share. The exercise price is what must be paid per share if and when the option is exercised in the future.

How many derivative securities does Donovan Daniel hold in INTS after this option grant?

Following this grant, the Form 4 shows 5,500 derivative securities held directly by Donovan Daniel, corresponding to the newly awarded stock option. These represent rights to acquire an equal number of Intensity Therapeutics common shares, subject to vesting and the 2036 expiration date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/20/2026 - 04:03 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Donovan Daniel

(Last) (First) (Middle)

C/O INTENSITY THERAPEUTICS, INC.

1 ENTERPRISE DRIVE, SUITE 430

(Street)

SHELTON CONNECTICUT 06484

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
INTENSITY THERAPEUTICS, INC. [ INTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy Common Stock)	$4.9	07/16/2026		A		5,500		07/16/2026(1)	07/16/2036	Common Stock	5,500	$0	5,500	D

Explanation of Responses:

1. This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2026.

Remarks:

	/s/ Kostantinos Skordalos, Attorney-in-fact	07/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)